Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | CNR2 | P34972 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 4/20 | 0.62 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258322 | 0.83 | SMN1; SMN2 (0.82) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL5623445 | 0.83 | CNR2 (1.00) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL29717171 | 0.81 | CNR2 (0.73) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL4252422 | 0.79 | SMN1; SMN2 (0.77) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL13870899 | 0.78 | TP53 (0.81) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL14367406 | 0.77 | CNR2 (1.00) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL14367365 | 0.76 | KMT2A (0.70) | RAB9ACNR2MAPTNPC1KMT2A | |
| SCHEMBL5794352 | 0.75 | CNR2 (0.82) | RAB9ACNR2MAPTALDH1A1NPC1 | |
| SCHEMBL5624009 | 0.75 | CNR2 (1.00) | RAB9ACNR2MAPTNPC1SMN1; SMN2 | |
| SCHEMBL5651438 | 0.75 | CNR2 (0.67) | RAB9ACNR2MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | RAB9A 537/4885CNR2 1971/4885MAPT 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.